Company: EUDAW
Filing Date: 2025-04-29
Form Type: 20-F
Source: 0001641172-25-006627
Chunk: 5

Company: EUDA Health Holdings Ltd
Filing Date: 2025-04-29
Form: 20-F
Item: Item 3
Chunk 5
---
 Act Section 404. If existing material weaknesses or control deficiencies are not remediated or if material
weaknesses or control deficiencies occur in the future, EUDA may be unable to report the Company’s financial results accurately
on a timely basis or help prevent fraud, which could cause EUDA’s reported financial results to be materially misstated and result
in the loss of investor confidence or delisting and cause the market price of EUDA’s ordinary shares to decline. If we have material
weaknesses in the future, it could affect the financial results that the Company reports or create a perception that those financial
results do not fairly state EUDA’s financial position or results of operations. Either of those events could have an adverse effect
on the value of the Company’s ordinary shares.

Further,
even if EUDA concludes that our internal control over financial reporting provides reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with U. S. GAAP, because of its inherent
limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required
new or improved controls, or difficulties encountered in their implementation, could harm the Company’s results of operations or
cause EUDA to fail to meet future reporting obligations.

EUDA
will require additional funding through sale of either debt or equity securities to support its continuing operations and growth of business,
and such funding may not be available on acceptable terms, or at all, and that may adversely impact EUDA’s business, financial
condition, results of operations and growth potential.

EUDA’s
operations have consumed substantial funds since inception. It will continue
to require substantial funding to support its continuing operations. The Company also intends to continue to make significant investments
to support business growth, respond to business challenges or opportunities, expand its products and services offerings, and potentially
acquire complementary businesses and technologies. EUDA may seek to use equity or debt financings to raise additional funds to support
its continuing operations and support growth initiatives. In February 2023, Alfred Lim, Executive Director of EUDA, provided a working
capital loan in the amount of $128,750 to EUDA. From January to May 2023, James Tan, the former Chief Executive officer of 8i loaned the
Company with an aggregate amount of $500,700. In May 2023, EUDA initiated efforts to raise up to $4,000,000 from the sale of ordinary
shares at